A Form 4 filed on November 2, 2026, discloses that John W. Frederick, a director of Tempest Therapeutics, Inc. (NASDAQ:TPST), was granted a stock option to purchase 25,000 shares of common stock on October 13, 2026, at an exercise price of $0.74 per share.
Director John W. Frederick filed an initial statement of beneficial ownership with the SEC on November 2, 2026, reporting his holdings in Tempest Therapeutics, Inc. as of the event date of October 13, 2026.
Micheal G. Dunn, a newly appointed director of MPLX GP LLC, filed a Form 3 initial statement of beneficial ownership with the SEC on November 2, 2026, reporting zero directly held Common Units of MPLX LP as of the triggering event date of November …
Bruce L. Niemeyer filed an Initial Statement of Beneficial Ownership with the SEC on November 2, 2026, disclosing his status as a newly reporting director of MPLX LP, effective November 1, 2026.
Charles Silberstein, Chief Financial Officer of NovaBridge Biosciences, filed an initial statement of beneficial ownership on November 2, 2026, reporting no securities beneficially owned.
William Todd Horich, SVP of Commercial Operations at Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.
Frank Mottola, SVP and Chief Technology Operations Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.
Supernus Pharmaceuticals, Inc. Senior Vice-President and CFO Timothy C. Dec filed a Form 4 on November 2, 2026, disclosing the acquisition of 70,000 restricted stock units on October 30, 2026.
Supernus Pharmaceuticals President and CEO Jack A. Khattar filed a Form 4 on November 2, 2026, disclosing the acquisition of 400,000 restricted stock units on October 30, 2026, with vesting tied to the closing of a planned merger with Indivior Pharmaceuticals, Inc.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., reported the acquisition of 70,000 restricted stock units on October 30, 2026, in a Form 4 filed with the SEC on November 2, 2026.